PPARA and metabolic dysfunction-associated steatohepatitis: Another PPARα/γ agonist, saroglitazar, provided encouraging results in vitro and then in animal models, with a reduction in lipid deposition as well as collagen and α-SMA production in a NASH mouse model [188].